Immunofluorescence versus ELISA for the detection of antinuclear antigens

Expert Review of Molecular Diagnostics

Volumn 2, Issue 3, 2002, Pages 226-232

  Rondeel, Jan M M ^a  

^a Department of Clinical Chemistry ^*  (Netherlands)

Author keywords

ANA; Antinuclear antigens; Autoimmune disease; Clinical chemistry connective tissue disease; ELISA; Immunofluorescence; Laboratory; Predictive value; Recombinant; Sensitivity; Specificity

Indexed keywords

CELL NUCLEUS ANTIGEN;

AUTOIMMUNE DISEASE; CONNECTIVE TISSUE DISEASE; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOFLUORESCENCE; LABORATORY DIAGNOSIS; PREDICTION; REVIEW;

EID: 0036082994     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737159.2.3.226     Document Type: Review

References (42)

1. Laboratory diagnosis and monitoring in chronic systemic autoimmune diseases
2. Use and interpretation of rheumatologic tests: A guide for clinicians
3. Specificity of antiSm antibodies by ELISA for systemic lupus erythematosus: Increased sensitivity of detection using purified peptide antigens
4. Sensitivity and specificity of antiJo 1 antibodies in autoimmune diseases with myositis
5. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus
6. Mixed connective tissue disease and overlap syndromes
7. Assessment of the European classification criteria for Sjogren's syndrome in a series of clinically defined cases: Results of a prospective multicentre study
8. Different strategies in the laboratory diagnosis of autoimmune disease immunofluorescence, enzyme-linked immunosorbent assay or both?
9. The diagnostic value of antinuclear antibody testing
10. Evaluation of diagnostic tests for antinuclear antibodies in rheumatological practice
11. Laboratory testing for systemic rheumatic diseases
12. Usefulness of antinuclear antibody testing to screen for rheumatic diseases
13. Antinuclear antibodies: Clinical correlations and biologic significance
14. Cascade testing for autoantibodies in connective tissue diseases
15. Range of antinuclear antibodies in 'healthy' individuals
16. Antinuclear, anticytoplasmic and antiSjögren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors
17. Routine immunofluorescence detection of Ro/SS-A autoantibody using HEp-2 cells transfected with human 60 kDa Ro/SS-A
18. Neural differentiation of the human neuroblastoma cell line IMR32 induces production of a thyrotropin-releasing hormone-like peptide
19. Antineutrophil cytoplasmic antibodies
20. The antinuclear antibody test. When is a positive result clinically relevant?
21. Clinical features and evolution of antinuclear antibody positive individuals in a rheumatology out-patient clinic
22. Detection of antinuclear antibodies from patients with systemic rheumatic diseases by ELISA using HEp-2 cell nuclei
23. HEp2 ANA EIA: A new fully automated assay for the screening of antinuclear antibodies
24. Recombinant 52 kDa Ro(SSA) ELISA detects autoantibodies in Sjogren's syndrome sera that go undetected by conventional serologic assays
25. Detection of autoantibodies to nuclear antigens by EIA and IF techniques
26. Determination of antibodies to extractable nuclear antigens with commercial kits: A multicenter study
27. Differences in clinical sensitivity of ELISA tests for autoantibodies with human and bovine extractable nuclear antigens
28. Evaluation of commercial enzyme immunoassays compared to immunofluorescence and double diffusion for autoantibodies associated with autoimmune disease
29. Comparison and variation of different methodologies for the detection of autoantibodies to nuclear antigens (ANA)
30. Comparison of antinuclear antibody testing methods by ROC analysis with reference to disease diagnosis
31. Clinical siginificance of antinuclear antibodies: Comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays
32. Detection of antinuclear antibodies: Comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods
33. A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity and specificity
34. The use of laboratory tests in the diagnosis of SLE
35. Antinuclear antibody screening in this new millennium: Farewell to the microscope?
36. Immunofluorescence assays (IFA) and enzyme-linked immunosorbent assays (ELISA) in autoimmune disease diagnostics-technique, benefits, limitations and applications
37. Evaluation of a recombinant antigen enzyme linked immunosorbent assay (ELISA) in the diagnostics of antinuclear antibodies (ANA) in children with rheumatic disorders
38. Performance characteristics and clinical utility of a hybrid ELISA for detection of ANA
39. Immunofluorescence-still the 'gold standard' in ANA testing?
40. Antinuclear antibody determination in a routine laboratory
41. Guidelines for clinical use of the antinuclear antibody test as tests for specific autoantibodies to nuclear antigens
42. A practical guide for serologic evaluation of autoimmune connective tissue diseases